Spinal and Bulbar Muscular Atrophy clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients
open to eligible males ages 18 years and up
This is a phase 1/2a randomized, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of study drug AJ201 in subjects with Spinal and Bulbar Muscular Atrophy (SBMA).
at UC Irvine
Our lead scientists for Spinal and Bulbar Muscular Atrophy research studies include Tahseen Mozaffar, MD.
Last updated: